Panitumumab monotherapy for gemcitabine, TS-1 and CDDP tolerant or failure unresectable or recurrent cholangiocarcinoma, evaluation of safety and efficiency.
Phase of Trial: Phase I/II
Latest Information Update: 02 Apr 2014
At a glance
- Drugs Panitumumab (Primary)
- Indications Cholangiocarcinoma
- Focus Therapeutic Use
- 22 Oct 2011 Actual initiation date changed from Sep 2011 to Apr 2012 as reported by University Hospital Medical Information Network - Japan.
- 05 Sep 2011 New trial record